Hologic Inc. today announced that it has successfully completed its sale of the LIFECODES business unit to Immucor Inc.
Hologic has received $85 million in cash (adjusted for working capital items) with the opportunity to earn a contingent payment of $10 million based on the achievement of certain financial targets for the calendar year 2013. The closing follows the receipt of all necessary regulatory approvals.
LIFECODES provides a product portfolio for the transplant laboratory, with screening, ID, and single-antigen kits designed to detect and identify HLA antibodies in serum.
Immucor markets a line of traditional immunohematology reagents and fully automated instruments, as well as data-management software to drive efficiency and productivity in the field of transfusion medicine.
More information about the LIFECODES business is on Gen-Probe's website.
More information about Immucor and its assimilation of LIFECODES is on Immucor's website.